REVEAL GENOMICS® ANNOUNCES POSITIVE TOP-LINE RESULTS FOR HER2DX® IN MEDSIR'S PHERGAIN TRIAL
Barcelona, Spain (ots/PRNewswire) - - HER2DX® pCR-score was significantly associated with pathological complete response in patients with HER2+ breast cancer treated with trastuzumab and pertuzumab, with or without chemotherapy. - HER2DX® risk-score identified 85% of patients with an invasive disease event as ...
mehr